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received: adalimumab 40mg every other week (eow) + MTX;
adalimumab 40mg eow; or MTX monotherapy. The Short Form
36 (SF-36) was used to assess 8 domains of HRQOL at baseline,
and after 12, 26, 42, 52, 76, and 104 weeks of therapy (higher
scores indicate improvement). Scores for 4 physical and 4 mental
health concepts were aggregated into Physical Component
Summary (PCS) and Mental Component Summary (MCS)
scores. A minimum clinically important difference (MCID) is
2.5–5.0 for PCS and MCS. Criteria-based interpretation of the
PCS evaluated relationships between clinically and socially
meaningful variables. RESULTS: Baseline scores for the 799
patients were comparable between all 3 groups, and post-base-
line results were comparable for the 2 monotherapy groups.
Mean baseline PCS for the adalimumab + MTX (n = 256) and
MTX monotherapy (n = 247) groups were 31.7 and 32.2. Mean
PCS for the combination therapy group at Week 12 had
improved to 42.2 vs. 38.2 for the MTX group. The 4.5 differ-
ence in mean change from baseline was clinically meaningful and
sustained through 2 years (5.1) (p < 0.0001). Based on criteria-
based interpretation of the SF-36, differences in PCS scores
between the 2 groups indicate patients on MTX alone had an
increased likelihood of using more health resources and not
being able to work. CONCLUSIONS: Adalimumab + MTX
were superior to MTX alone in providing signiﬁcant and clini-
cally meaningful improvements in HRQOL in early RA. Signif-
icantly lower PCS at 2 years in the MTX group may mean
patients on MTX alone have greater health care utilization and
substantially greater job loss than patients on combination
therapy.
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OBJECTIVES: To investigate the ability of adalimumab therapy
to provide simultaneous, sustained long-term improvement in
two important patient-reported outcomes (health utility and
fatigue) in patients with severe RA who had failed at least one
DMARD. METHODS: The Health Utilities Index Mark 3
(HUI3) and Fatigue (FACIT-F, validated in RA) were simultane-
ously measured in a health economics companion trial to an
adalimumab pivotal study (DE011). For the ﬁrst 26 weeks
patients were followed under double-blind, randomized condi-
tions before rolling over into a long-term, open-label extension
(OLE) (n = 99). A subset of patients receiving adalimumab 40
mg every other week was evaluated for up to 170 weeks. The
HUI3 scale is 0–1, with “1” denoting perfect health and “0”
denoting death. FACIT-F scores range from 0–52, with higher
scores representing less fatigue. Changes in HUI3 of ≥0.03 and
FACIT-F of ≥4 are considered clinically meaningful. RESULTS:
Baseline patient characteristics were: female, 80%; age, 53 years;
duration of disease, 10 years; TJC (0–68), 34; SJC (0–66), 21;
HAQ score, 1.9; C-reactive protein (mg/L), 54; number of pre-
vious DMARDs: 4 (all mean values except % female). RA
patients’ baseline utility and fatigue scores were comparable (vs.
placebo) and approximately one-third of the population norm.
At week 26, mean changes from baseline in adalimumab-treated
patients were 0.18 for HUI3, and 8.54 for FACIT-F (both p <
0.001 vs. baseline). These improvements were sustained through-
out week 170. CONCLUSIONS: Adalimumab provided clini-
cally important, simultaneous improvements in health utility and
fatigue in patients with severe, active RA who had failed at least
one DMARD. These improvements were sustained over the 3-
year observation period.
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OBJECTIVE: To compare the efﬁcacy of regular treatment with
BUD/FM plus BUD/FM prn versus regular treatment with budes-
onide (BUD) and formoterol (FM) plus FM prn in the treatment
of asthmatic patients in Greece. METHODS: Moderate asth-
matic (mean FEV1 76% pred.) patients were recruited from 14
centers in Greece to participate in an open-label, randomized
prospective clinical trial. The duration of the study was seven
months with four scheduled visits: baseline, ﬁrst month, third
month and seventh month. Patients were randomized in 2
groups: Group A: BUD/FM 160/4.5 ìg bid plus BUD/FM prn and
Group B: BUD 200 ìg and FM 9 ìg bid plus FM prn. Outcome
measures included lung function, number of exacerbations and
relief inhalations, symptom control using the Asthma Control
Questionnaire (ACQ) and quality of life using the Asthma
Quality of Life Questionnaire (AQLQ). In addition, the use of
health services and side effects were recorded. RESULTS: A total
of 133 patients were recruited, 68 in Group A, and 65 in Group
B. Both groups showed a signiﬁcant improvement in ACQ at the
end of the study (p < 0.0001). Relief inhalations were signiﬁ-
cantly less in Group A (p < 0.0001) during the last study period,
between 3rd and 7th month. No statistically signiﬁcant differ-
ences were found in the other outcome measures. CONCLU-
SIONS: BUD/FM therapy plus BUD/FM as needed demonstrated
similar effectiveness in asthma control and quality of life com-
pared to treatment with BUD and FM plus FM as needed. Since
fewer relief inhalations were recorded in Group A, BUD/FM plus
BUD/FM prn treatment seems preferable for patients with
asthma.
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OBJECTIVE: To investigate whether salmeterol/ﬂuticasone pro-
pionate 50/100mcg (SFC) improves quality of life, physical func-
tioning and asthma symptoms in children with uncontrolled
asthma in primary care. METHODS: A prospective open label
study of children seven to twelve years old attending their GP
with uncontrolled asthma. SFC bd was taken for 16 weeks (w)
from enrolment. Peak expiratory ﬂow rate (PEFR) was measured
at baseline, w4 and w16, when the Paediatric Asthma Quality
of Life Questionnaire (PAQLQ) was completed. Patient diaries
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recorded symptom scores, use of rescue medication, and time off
school and parental time off work due to asthma. RESULTS: A
total of 35 patients participated. Mean age: 9.8yrs, mean time
since diagnosis: 6.2yrs. At w16 compared with w0: Mean PEFR
increased by 59.2 l/min*; all PAQLQ domain and overall scores
improved >=2 points*; mean day and night time symptoms
scores improved by 1.5 points* and 1.6* points respectively;
patients reported a mean of 3.9 more days per week without
asthma symptoms* and 4.6 fewer days per week using short
acting b2 agonist medication*; children missed 1.6 fewer school
days per month, and carers missed a mean of 1.2 fewer days per
month from work*. No treatment related adverse events were
reported. CONCLUSION: SFC signiﬁcantly improved asthma
symptoms, quality of life and daily activities of uncontrolled
pediatric asthma patients and their families. *P < 0.05
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OBJECTIVE: The aim of this study was to assess the degree of
asthma control in Spain in accordance with the GINA criteria.
METHODS: An epidemiological cross-sectional multicenter
study was performed. A representative sample of consecutive
patients with asthma over 18 years attending primary care and
specialist ofﬁces were enrolled. Patients were seen in winter and
spring and were asked on their asthma control in the four weeks
prior to the visit according to the GINA criteria. Control was
deﬁned based on the patient’s day and night symptoms.
RESULTS: A total of 614 patients participated in the study.
Patients presented every day or most days in the four weeks prior
to the winter and spring visit daytime symptoms (40.3% vs.
22.5%) (p < 0.01), night-time symptoms (27.8% vs. 13.9%) 
(p < 0.01)), severe exacerbation episodes (11.9% vs. 8.8%) and
intolerance to exercise (32.9% vs. 35.5%). The proportion of
patients with emergency visits in the four weeks prior to the 
visit was 9.1% vs. 4.2% (p < 0.01) respectively. The most fre-
quently used treatment was the combination of inhaled corti-
costeroids and long-acting b2 adrenergic agonists (49.8% vs.
49%). There were a slightly higher number of inadequately 
controlled patients in winter than spring, 74.2% vs. 71.1% 
(p < 0.01) respectively. CONCLUSION: Asthma is poorly con-
trolled in Spain, with the need for improvements in the man-
agement of the disease.
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OBJECTIVES: A literature search revealed only a few published
retrospective database analyses in which the yearly cost of
asthma was compared for patients with and without asthma
attacks. This however does not allow estimating the health care
utilization associated with a single exacerbation. In contrast, this
study aims to analyze resource use collected during a random-
ized, double-blind trial and to estimate the costs of a mild and
a severe asthma exacerbation. METHODS: The INNOVATE
trial randomized severe persistent allergic asthma patients who
were inadequately controlled despite inhaled corticosteroid (ICS)
and long-acting beta2-agonist (LABA) to continued standard
therapy (N = 210) or to add-on therapy with omalizumab (N =
209). Resource use was recorded on the CRF and with daily
patient diaries. Data from both treatment arms were pooled to
calculate average resource use for clinically signiﬁcant (worsen-
ing of asthma symptoms requiring systemic steroids) mild (PEF
or FEV1 >= 60% of personal best) or severe (PEF or FEV1 <
60% of personal best) exacerbations from a UK NHS perspec-
tive. Patients were observed for a total of 36 weeks (including 8
weeks run-in). Standard unit costs (PSSRU, NHS Reference
Costs, 2004) were applied to calculate the exacerbation-related
cost. RESULTS: A total of 419 patients experienced 195 mild
and 204 severe exacerbations during the observation period,
lasting on average 12.8 days each. Resource use was measured
in terms of GP surgery visits, ER visits, outpatient visits, hospi-
talizations and rehabilitation visits. The average cost of a clini-
cally signiﬁcant mild exacerbation is estimated to be £99, and of
a severe exacerbation is £197. CONCLUSIONS: Exacerbations
are costly and frequently occurring events in a severe persistent
allergic asthma population. Decreasing the frequency and sever-
ity of exacerbations improves patients’ health outcomes and
reduces resource use, which could be quantiﬁed with this
approach.
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Montelukast is recognised to be an effective and safe therapy for
the treatment of mild to moderate asthmatic patients with con-
comitant seasonal allergic rhinitis. OBJECTIVES: to evaluate
asthma-related direct costs in patients with mild to moderate per-
sistent asthma and seasonal allergic rhinitis (AR) in Spain, whose
asthma was inadequately controlled and required the addition of
montelukast as part of their routine care. METHODS: a multi-
center, 12 months pre-post observational study was conducted,
selecting mild to moderate asthmatic consecutive patients with
previous inhaled corticosteroid (ICS) w/wo LABAs therapy, who
initiated concomitant montekulast between January 1999 and
December 2002. Asthma-related health care resources data was
collected retrospectively, including medication, medical visits, 
ER visits and hospitalizations. For the costing calculations,
natural units were multiplied by unit costs, and conﬁdence inter-
vals (CI) calculated using bootstrapping analysis. RESULTS:
212 patients (mean age 36.0(SD 9.7), 56.6% female, 50.9% 
mild asthmatics) were recruited in 55 sites (54.5% Primary 
Care, 34.5% Allergologists and 11% Pneumologists) across the
country. After initiation of montelukast therapy, all other
asthma-related health care resource categories did show a sig-
niﬁcant reduction (p < 0.01) (mean reduction in 2004€; 95%
CIs): medication (146.1; 78.8–225.2); outpatient visits (57.5;
44.5–76.8), ER visits (61.1; 48.4–84.4) and hospitalizations
(243; 86.2–875.4), total 508.3 95% CI 348.3–969.9. Addition-
ally considering the montelukast treatment cost during 365 days,
the reduction achieved in all other asthma-related health care
resources would compensate for 92.7% of the montelukast cost.
CONCLUSIONS: montelukast therapy was associated with a
signiﬁcant reduction in all other asthma-related health care
resources use in patients with mild to moderate asthma and con-
comitant seasonal allergic rhinitis.
